Power to detect clinically relevant carry-over in a series of cross-over studies

Statistics in Medicine

Volumn 25, Issue 15, 2006, Pages 2567-2586

  Putt, Mary E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bioequivalence; Carry over effects; Clinical trials; Cross over trial; Meta analysis

Indexed keywords

DONEPEZIL; NARCOTIC ANALGESIC AGENT; VERAPAMIL;

ANALYTICAL ERROR; ARTICLE; BIOEQUIVALENCE; BIOSTATISTICS; CALCULATION; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; CROSSOVER PROCEDURE; DYSPNEA; HUMAN; HYPOTHESIS; METHODOLOGY; POWER ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

CROSS-OVER STUDIES; HUMANS; MODELS, STATISTICAL; THERAPEUTIC EQUIVALENCY;

EID: 33746121857     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2275     Document Type: Article

References (28)

1. Vonesh E, Chinchilli V. Linear and Nonlinear Models for the Analysis of Repeated Measurements. Marcel Dekker: New York, 1997.
2. Senn S. Crossover Trials in Clinical Research (2nd edn). Wiley: New York, 2002.
3. Chow SC, Liu J. Design and Analysis of Bioavailability and Bioequivalence Studies (2nd edn). Marcel Dekker Inc.: New York, 2000.
4. Freeman PR. The performance of the two-stage analysis of two-treatment, two-period cross-over trials. Statistics in Medicine 1989; 8:1421-1432.
5. Wang SJ, Hung HMJ. Use of two-stage test statistics in the two-period crossover trials. Biometrics 1997; 53:1081-1091.
6. United States Food and Drug Administration. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Accessed January 2001 http://www.fda.gov/cder/guidance/3616fnl.htm#P353_2704.
7. Carriere KC, Reinsel GC. Investigation of dual-balanced crossover designs for two treatments. Biometrics 1992; 48:1157-1164.
8. Putt ME, Ravina B. Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease. Controlled Clinical Trials 2002; 23:111-126.
9. Garcia R, Benet M, Arnau C, Cobo E. Efficiency of the cross-over design: an empirical estimation. Statistics in Medicine 2004; 23:3773-3780.
10. Lagakos S. Clinical trials and rare disease. New England Journal of Medicine 2003; 384:2455-2456.
11. Conway E. A review of the randomized controlled trials of tacrine in the treatment of Alzheimer's disease: methodologic considerations. Clinical Neuropharmacology 1998; 21:8-17.
12. Brown B. The cross-over experiment for clinical trials. Biometrics 1980; 36:69-79.
13. Grizzle JE. The two-period change over design and its use in clinical trials. Biometrics 1965; 21:467-480.
14. Grizzle JE. Correction to Grizzle. Biometrics 1974; 30:727.
15. D'Angelo G, Potvin D, Turgeon J. Carry-over effects in bioequivalence studies. Journal of Biopharmaceutical Statistics 2001; 11:35-43.
16. Senn SG, D'Angelo G, Potvin D. Carry-over in cross-over trials in bioequivalence: theoretical concerns and empirical evidence. Pharmaceutical Statistics 2004; 3:133-142.
17. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over clinical trials. I: continuous outcomes. Statistics in Medicine 2002; 21:2131-2144.
18. Curtin F, Elbourne DG, Altman D. Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over. Statistics in Medicine 2002; 21:2161-2173.
19. Elbourne DR, Altman DG, Higgins, Curtin F, Worthington H, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002; 31:140-149.
20. Ahrens RC, Teresi ME, Han S, Donnell D, Vanden Burgt J, Lux CR. Asthma stability after oral prednisone. Respiratory and Critical Care Medicine 2001; 164:1138-1145.
21. Bestall N, Jones PW. Inhaled beclomethasone versus budesonide for chronic asthma (Cochrane Review). The Cochrane Library 2003; Issue 4. Wiley: Chichester, U.K.
22. Hung HM, O'Neill R, Bauer P, Kohne K. The behavior of the p-value when the alternative hypothesis is true. Biometrics 1997; 53:11-22.
23. Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria. ISBN 3-900051-00-3. http:www.R-project.org.
24. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 1987; 15:657-680.
25. Bellavance F, Tardif S. A nonparametric approach to the analysis of three-treatment three-period crossover designs. Biometrika 82:865-875.
26. Diletti E, Hauscheke D, Steinijams VW. Sample size determination for bioequivalence assessments by means of confidence intervals. International Journal of Clinical Pharmacology, Therapy and Toxicology 1991; 29: 1-8.
27. Schall R, Luus HG. On population and individual bioequivalence. Statistics in Medicine 1993; 12:1109-1124.
28. Liu JP, Chow SC. On power calculation of Schuirmann's two one-sided tests procedure in bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 1992; 20:101-104.